This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Akbulut, T. Articles by Tayyareci, G. Search for Related Content PubMed PubMed Citation Articles by Akbulut, T. Articles by Tayyareci, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ENALAPRIL MALEATE LOSARTAN POTASSIUM Social Bookmarking                         What's this?

Evaluation of Enalapril+Losartan Treatment with Cardiopulmonary Exercise Test in Patients with Left Ventricular Dysfunction

Siyami Ersek Cardiothoracic Surgical Center, Cardiology Clinic, Istanbul, Turkey

Haldun Akgöz, MD

Siyami Ersek Cardiothoracic Surgical Center, Cardiology Clinic, Istanbul, Turkey, ufukgur01{at}hotmail.com

ennur Ünal Dayi, MD

Siyami Ersek Cardiothoracic Surgical Center, Cardiology Clinic, Istanbul, Turkey

Seden Erten Çelik, MD

Siyami Ersek Cardiothoracic Surgical Center, Cardiology Clinic, Istanbul, Turkey

Ufuk Gürkan, MD

Siyami Ersek Cardiothoracic Surgical Center, Cardiology Clinic, Istanbul, Turkey

Gülah Tayyareci, MD

Siyami Ersek Cardiothoracic Surgical Center, Cardiology Clinic, Istanbul, Turkey

The aim of this study was to evaluate the effects of the combination of enalapril and losartan in patients with left ventricular systolic dysfunction by means of cardiopulmonary exercise test (CPET). Patients with left-ventricular systolic dysfunction and ejection fractions of 40% or less were included to the study. All patients were under the treatment of enalapril 20 mg once daily. The study group consisted of 20 patients (18 men, 2 women; mean age ± standard deviation: 62.4 ±6.5 years) and the comparison group consisted of 10 (8 men, 2 women; mean age 59.3 ±11.9 years). The dose of 50 mg of losartan once daily was given additionally to the study patients. Breath-by-breath CPET was performed before administration of losartan and then 6-8 weeks later in the study group and 2 times with an interval of 6-8 weeks in the control group without any change in the treatment protocol. In the study group the average exercise times were 361 ±192 and 454 ±205 seconds (p=0.001) before and after the study. Peak oxygen consumption (O₂) values were 1,209 ±366 and 1,284 ±398 mL/minute before and after the study (p=0.01). Anaerobic threshold O₂ values were 785 ±187 and 855 ±217 mL/minute before and after the study, respectively (p=0.01). Peak heart rates (HR) were 141 ±28 and 143 ±22/minute (p=0.35); peak O₂/HR values were 9.02 ±3.1 and 9.3 ±3 mL/minute (p=0.4) before and after the study, respectively. On the other hand, in the control group, average exercise times were 556 ±250 and 528 ±251 seconds (p=0.8); peak O₂ values were 1,502 ±537 and 1,450 ±501 mL/minute (p=0.2); and anaerobic threshold O₂ values were 1,005 ±338 and 975 ±319 mL/min (p=0.7), before and after the study respectively. At the highest comparable exercise stage for both tests in the study group the expired volume/oxygen consumption (E/O₂) ratio declined from 35.1 ±6.2 to 32.4 ±5.6 (p=0.007). V E values declined from 37.5 ±10.9 to 33.9 ±10.1 L (p=0.02); heart rate declined from 140 ±27 to 132 ±21/minute (p=0.02). No significant change was observed in the mentioned values for the control group. Addition of losartan to the standard therapy in patients with left ventricular systolic dysfunction improved exercise capacity and caused lower heart rate and ventilation requirements for the same exercise level.

References

• Kannet WB, Belanger AJ: Epidemiology of heart failure. Am Heart J 121:951-957, 1991.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The CONSENSUS Trial study group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 316:1429-1435, 1987.[Abstract]
• The SOLVD Investigators: Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293-302, 1991.[Abstract]
• Pfeffer MA, Braunwald E, Myoe LA, et al: The effects of captopril on mortality and morbidity in patients with left ventricular dysfunction following myocardial infarction: Results of the Survival and Ventricular Enlargement (SAVE) trial. N Engl J Med 327:669-677, 1992.[Abstract]
• The Acute Infarction Ramipril Efficacy (AIRE) Study investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821-828, 1993.[Web of Science][Medline] [Order article via Infotrieve]
• Massie BM, Armstrong PW, Cleland J, et al: Toleration of high doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure: Results from the ATLAS trial. The assessment of treatment with lisinopril and survival. Arch Intern Med 22:165-171, 2001.
• Urata H, Healy B, Steward RW, et al: Angiotensin II forming pathways in normal and failing human hearts. Circ Res 66:883-890, 1990.[Abstract/Free Full Text]
• Balcells E, Meng QC, Johnson WH, et al: Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations. Am J Physiol 273:769-774, 1997.
• Jorde UP, Ennezat PV, Lisker J, et al: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 101:844-846, 2000.[Abstract/Free Full Text]
• Gottlieb SS, Dieckstein K, Fleck E, et al: Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 88:1602-1609, 1993.[Abstract/Free Full Text]
• Birkenhager BH, de Leeuw PW: Nonpeptide angiotensin type I receptor antagonists in the treatment of hypertension. J Hypertens 17:873-881, 1999.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Crozier I, Ikram H, Awa N, et al: Losartan in heart failure: Hemodynamic effects and tolerability. Circulation 91:691-697, 1995.[Abstract/Free Full Text]
• Wasserman K, Hansen JE, Sue DY, et al: Principles of Exercise Testing and Interpretation. Philadelphia: Lea & Febiger, 1994, pp 53-111.
• Pitt B, Segal R, Martinez FA, et al: Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747-752, 1997.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• The RESOLVD Pilot Study Investigators: Comparison of candesartan, enalapril and their combination in congestive heart failure. Circulation 100:1056-1064, 1999.[Abstract/Free Full Text]
• Tonkon M, Awan N, Niazi I, et al: A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clinical Pract 54:11-14, 16-18, 2000.
• Tocchi M, Rosanio S, Anzuini A, et al: Angiotensin II receptor blockade combined with ACE-inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure (abstract). J Am Coll Cardiol 188A:842-842, 1998.
• Hamroff G, Katz SD, Mancini D, et al: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 2;99:990-992, 1999.
• Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 6;345:1667-1675, 2001.
• Swedberg K, Pfeffer M, Granger C, et al: Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design. Charm-Programme Investigators. J Card Fail 5:276-282, 1999.[CrossRef][Medline] [Order article via Infotrieve]
• Fleg JL, Pina IL, Balady GJ, et al: Assessment of functional capacity in clinical and research applications. An advisory from the committee on exercise, rehabilitation and prevention, council on clinical cardiology, American Heart Association. Circulation 102: 1591-1597, 2000.[Free Full Text]

Angiology, Vol. 57, No. 2, 181-186 (2006)
DOI: 10.1177/000331970605700207


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (2) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Akbulut, T. Articles by Tayyareci, G. Search for Related Content PubMed PubMed Citation Articles by Akbulut, T. Articles by Tayyareci, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ENALAPRIL MALEATE LOSARTAN POTASSIUM Social Bookmarking                         What's this?